KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Repurchased
Ratios

GoodRx Holdings (GDRX) EBIAT (2019 - 2025)

Historic EBIAT for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • GoodRx Holdings' EBIAT fell 7177.81% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 29578.27%. This contributed to the annual value of $16.4 million for FY2024, which is 28482.18% up from last year.
  • Per GoodRx Holdings' latest filing, its EBIAT stood at $1.1 million for Q3 2025, which was down 7177.81% from $12.8 million recorded in Q2 2025.
  • Over the past 5 years, GoodRx Holdings' EBIAT peaked at $58.8 million during Q2 2023, and registered a low of -$41.7 million during Q3 2022.
  • Over the past 5 years, GoodRx Holdings' median EBIAT value was $1.1 million (recorded in 2025), while the average stood at -$1.3 million.
  • The largest annual percentage gain for GoodRx Holdings' EBIAT in the last 5 years was 425448.76% (2023), contrasted with its biggest fall of 121181.54% (2023).
  • GoodRx Holdings' EBIAT (Quarter) stood at -$39.9 million in 2021, then skyrocketed by 95.06% to -$2.0 million in 2022, then plummeted by 1211.82% to -$25.9 million in 2023, then surged by 126.05% to $6.7 million in 2024, then tumbled by 83.4% to $1.1 million in 2025.
  • Its EBIAT stands at $1.1 million for Q3 2025, versus $12.8 million for Q2 2025 and $11.1 million for Q1 2025.